Mechanisms of rejection: Current perspectives

Transplantation

Volumn 93, Issue 1, 2012, Pages 1-10

  Wood, Kathryn J ^a   Goto, Ryoichi ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adaptive; Allograft; Antibody; B cell; Cytotoxicity; Heart; Immunosuppression; Innate; Intestine; Islet; Kidney; Liver; Pancreas; T cell; Transplantation

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5A; HLA ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 21; MAJOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR;

ACUTE GRAFT REJECTION; ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; ENDOTHELIUM CELL; ERYTHROCYTE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HELPER CELL; HUMAN; IMMUNOLOGICAL MEMORY; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOID ORGAN; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

B-LYMPHOCYTES; GRAFT REJECTION; HUMANS; IMMUNITY, INNATE; ORGAN TRANSPLANTATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84655170198     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31823cab44     Document Type: Review

References (63)

1. Pallet N, Fougeray S, Beaune P, et al. Endoplasmic reticulum stress: An unrecognized actor in solid organ transplantation. Transplantation 2009; 88: 605.
2. Mühlberger I, Perco P, Fechete R, et al. Biomarkers in renal transplantation ischemia reperfusion injury. Transplantation 2009; 88: S14.
3. Famulski KS, Broderick G, Einecke G, et al. Transcriptome analysis reveals heterogeneity in the injury response of kidney transplants. Am J Transplant 2007; 7: 2483.
4. Kim IK, Bedi DS, Denecke C, et al. Impact of innate and adaptive immunity on rejection and tolerance. Transplantation 2008; 86: 889.
5. Bouma HR, Ketelaar ME, Yard BA, et al. AMP-activated protein kinase as a target for preconditioning in transplantation medicine. Transplantation 2010; 90: 353.
6. Hosgood SA, Nicholson ML. The role of perfluorocarbon in organ preservation. Transplantation 2010; 89: 1169.
7. Moers C, Varnav OC, van Heurn E, et al. The value of machine perfusion perfusate biomarkers for predicting kidney transplant outcome. Transplantation 2010; 90: 966.
8. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805.
9. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: First line of the immune response to cell stress. Cell 2006; 126: 659.
10. Anglicheau D, Muthukumar T, Suthanthiran M. MicroRNAs: Small RNAs with big effects. Transplantation 2010; 90: 105.
11. Carvalho-Gaspar M, Billing JS, Spriewald BM, et al. Chemokine gene expression during allograft rejection: Comparison of two quantitative PCR techniques. J Immunol Methods 2005; 301: 41.
12. Lo DJ, Weaver TA, Kleiner DE, et al. Chemokines and their receptors in human renal allotransplantation. Transplantation 2011; 91: 70.
13. Larsen C, Morris P, Austyn J. Migration of dendritic leukocytes form cardiac allografts into host spleens: A novel pathway for initiation of rejection. J Exp Med 1990; 171: 307.
14. van Kooten C, Lombardi G, Gelderman KA, et al. Dendritic cells as a tool to induce transplantation tolerance: Obstacles and opportunities. Transplantation 2011; 91: 2.
15. Boyd AS, Higashi Y, Wood KJ. Transplanting stem cells: Potential targets for immune attack. Modulating the immune response against embryonic stem cell transplantation. Adv Drug Deliv Rev 2005; 57: 1944.
16. Hara M, Kingsley C, Niimi M, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166: 3789.
17. Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: An analysis of United Network for Organ Sharing Registry Data. Transplantation 2010; 90: 1511.
18. Tan HP, Chaudhary A, Humar A, et al. Rejection characteristics of 200 living donor kidney transplantations using alemtuzumab pretreatment and tacrolimus monotherapy: Mean 5-year follow-up: 1338. Transplantation 2010; 90: 174.
19. Peugh WN, Superina RA, Wood KJ, et al. The role of H-2 and non-H2 antigens and genes in the rejection of murine cardiac allografts. Immunogenetics 1986; 23: 30.
20. Dierselhuis M, Goulmy E. The relevance of minor histocompatibility antigens in solid organ transplantation. Curr Opin Organ Transplantation 2009; 14: 419.
21. Afzali B, Lombardi G, Lechler RI. Pathways of major histocompatibility complex allorecognition. Curr Opin Organ Transplant 2008; 13: 438.
22. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23: 515.
23. Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: Challenges and new developments. Immunol Rev 2009; 229: 271.
24. Burrell BE, Bishop DK. Th17 cells and transplant acceptance. Transplantation 2010; 90: 945.
25. Barbara J, Turvery S, Kingsley C, Spriewald B, et al. Islet allograft rejection can be mediated byCD4+, alloantigen experienced direct pathway T cells or TH1 and TH2 cytokine phenotype. Transplantation 2000; 70: 1641.
26. Chen Y, Wood KJ. Interleukin-23 and TH17 cells in transplantation immunity: Does 23+17 equal rejection? Transplantation 2007; 84: 1071.
27. Heidt S, San Segundo D, Chadha R, et al. The impact of Th17 cells on transplant rejection and the induction of tolerance. Curr Opin Organ Transplant 2010; 15: 456.
28. Chadha R, Heidt S, Wood KJ. Th17: Contributors to allograft rejection and a barrier to the induction of transplantation tolerance? Transplantation 2011; 91: 939.
29. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008; 205: 3133.
30. Faust SM, Lu G, Marini BL, et al. Role of T cell TGF-α signaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection. J Immunol 2009; 183: 7297.
31. Long E, Wood KJ. Regulatory T cells in transplantation: Transferring mouse studies to the clinic. Transplantation 2009; 88: 1050.
32. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nature Immunol Rev 2003; 3: 199.
33. Long E, Wood KJ. Understanding FOXP3: Progress towards achieving transplantation tolerance. Transplantation 2007; 84: 459.
34. Tarlinton DM, Batista F, Smith KGC. The B-cell response to protein antigens in immunity and transplantation. Transplantation 2008; 85: 1698.
35. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol 2004; 5: 981.
36. Cyster JG. B cell follicles and antigen encounters of the third kind. Nat Immunol 2010; 11: 989.
37. Sarwal M, Chua M, Kambham N. Molecular heterogeneity in acute renal allograft rejection identified byDNAmicroarray profiling.NEngl J Med 2003; 349: 125.
38. Naesens M, Zarkhin V, Kambham N, et al. Evaluation of intra-graft B-cell subsets in renal allograft rejection: 664. Transplantation 2008; 86: 233.
39. Zarkhin V, Li L, Sarwal M. 'To B or not to B?' B-cells and graft rejection. Transplantation 2008; 85: 1705.
40. Kwun J, Knechtle SJ. Overcoming chronic rejection-Can it B? Transplantation 2009; 88: 955.
41. Thaunat O. Pathophysiologic significance of B-cell clusters in chronically rejected grafts. Transplantation 2011; 92: 121.
42. Scheepstra C, Bemelman FJ, van der Loos C, et al. B cells in cluster or in a scattered pattern do not correlate with clinical outcome of renal allograft rejection. Transplantation 2008; 86: 772.
43. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Investig 2010; 120: 1848.
44. Newell KA, Asare A, Kirk AD, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Investig 2010; 120: 1836.
45. Le Texier L, Thebault P, Lavault A, et al. Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile. Am J Transplant 2011; 11: 429.
46. Li XC. The significance of non-T-cell pathways in graft rejection: Implications for transplant tolerance. Transplantation 2010; 90: 1043.
47. Asgari E, Zhou W, Sacks S. Complement in organ transplantation. Curr Opin Organ Transplant 2010; 15: 486.
48. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807.
49. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med 2010; 363: 1451.
50. Lanier LL. Up on the tightrope: Natural killer cell activation and inhibition. Nat Immunol 2008; 9: 495.
51. Kitchens WH, Uehara S, Chase CM, et al. The changing role of natural killer cells in solid organ rejection and tolerance. Transplantation 2006; 81: 811.
52. Summers C, Rankin SM, Condliffe AM, et al. Neutrophil kinetics in health and disease. Trends Immunol 2010; 31: 318.
53. Kitchens WH, Chase CM, Uehara S, et al. Macrophage depletion suppresses cardiac allograft vasculopathy in mice. Am J Transplant 2007; 7: 2675.
54. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: Present and future therapeutic targets. Nat Immunol 2005; 6: 1182.
55. Anglicheau D, Suthanthiran M. Noninvasive prediction of organ graft rejection and outcome using gene expression patterns. Transplantation 2008; 86: 192.
56. Bedi DS, Riella LV, Tullius SG, et al. Animal models of chronic allograft injury: Contributions and limitations to understanding the mechanism of long-term graft dysfunction. Transplantation 2010; 90: 935.
57. Win TS, Pettigrew GJ. Humoral autoimmunity and transplant vasculopathy: When allo is not enough. Transplantation 2010; 90: 113.
58. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: From association to causation. Transplantation 2008; 86: 377.
59. Motallebzadeh R, Bolton EM, Pettigrew GJ. Lymphoid tissue formation in allografts: Innocent until proven guilty. Transplantation 2008; 85: 309.
60. Motallebzadeh R, Rehakova S, Goddard M, et al. Allograft tertiary lymphoid organ development requires humoral immunity [abstract 2524]. Transplantation 2010; 90: 485.
61. Thaunat O, Deteix C, McGregor B, et al. Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection [abstract 2898[. Transplantation 2010; 90: 151.
62. Brook M, Wood K, Jones N. The impact of memory T cells on rejection and tolerance. Transplantation 2006; 82: 1.
63. Adams A, Williams MA, Jones T, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Investig 2003; 111: 1887.